Mirum Pharmaceuticals price target raised to $148 from $142 at RBC Capital
RBC Capital analyst Lisa Walter raised the firm's price target on Mirum Pharmaceuticals to $148 from $142 and keeps an Outperform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has picked up considerable momentum, with a near-unprecedented two-week move in